Monthly Publications
In Depth
Subscribe Now
In Depth
coverage of timely
Life Science
Compliance issues
Subscribe Now
Browsing Category
HHS-OIG
Johnson and Johnson Corporate Integrity Agreement: The Progression of Life…
Compliance managers at pharmaceutical companies and medical device manufacturers can stay ahead of enforcement trends by…
HHS OIG Reports CMS Not Catching All Overpayments
As reported by FierceHealth, a recent report by the Office of Inspector General claimed the Centers for Medicare &…
Johnson and Johnson 2013 Settlement and Corporate Integrity Agreement
On November 4, 2013, the Department of Justice (DOJ) announced that Johnson & Johnson (J&J) and its pharmaceutical…
Physician-Owned Distributors: Reliance Medical Systems Files Suite…
In April of this year, we reported on a new Special Fraud Alert regarding physician-owned distributorships (PODs) issued by the…
FDLI 2013: Insights in Enforcement, Litigation & Compliance for…
The Food and Drug Law Institute (FDLI) recently held its annual Advertising & Promotion Conference, which included in-depth…
False Claims Act: External Auditor Moonlights as Whistle Blower
Over the last several years, we have covered a broad array of settlements, legal cases, and government investigations and…
Senate Committee on Homeland Security and Governmental Affairs Hearing:…
Gary Cantrell, Deputy Inspector General for Investigations, and Stuart Wright, Deputy Inspector General for Evaluation and…
Summary of Recent Settlements Novartis, Amgen and Boehringer Ingelheim
The healthcare fraud settlements just keep rolling in. Recently, federal healthcare enforcement authorities settled several cases…
HHS OIG: Hospital Compliance Programs
The Office of Inspector General (OIG) for the U.S. Department of Health and Human services (HHS) recently did a podcast on…
ISTA Settlement Includes Divestiture and Debarment
In what has been one of the less prominent drug-settlements in recent times, the federal government recently entered…